Influence of Argipressin on blood loss and inflammatory response during hepatic resection; a double blinded, randomized, placebo-controlled trial

Sahlgrenska University Hospital0 个研究点目标入组 248 人开始时间: 2021年11月3日最近更新: 2023年11月20日

适应症

试验速览

暂无简介。

•1.Participant planned for hepatic resection (open or laparoscopic, regardless of indication for surgery).
•2.Age =18 years.
•3.ASA class I-III.
•4.Signed informed consent form
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 124
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 124

•1.Participant does not understand the given information, and/ or cannot give written informed consent.
•2.Simultaneous operation of tumor with other localization, or surgery for superficial single hepatic tumor less than 2 cm, expected to be of short duration and with minimal blood loss.
•3.Terminal kidney failure (estimated preoperative GFR< 15 ml/min)
•4.Pregnancy or lactation.
•5.Known allergy to Empressin®.
•6.Patient included in other interventional study, interacting with the endpoints in the present study, or previous randomization in this study.
•7.Hyponatremia (S-Na < 130 mmol/L)
•8.Patient considered ineligible for other surgical or medical reason.
•9.Present infection
•Patients with systemic inflammatory disease, inflammatory bowel disease or preoperative corticosteroid treatment will not be eligible for the subgroups (extended testing) where cytokines and interleukins are investigated

发起方

Sahlgrenska University Hospital